Research programme : enzyme replacement therapy - Swedish Orphan Biovitrum (Sobi)

Drug Profile

Research programme : enzyme replacement therapy - Swedish Orphan Biovitrum (Sobi)

Alternative Names: SOBI-003

Latest Information Update: 21 Oct 2016

Price : $50

At a glance

  • Originator Swedish Orphan Biovitrum
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis III
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inborn error metabolic disorders

Most Recent Events

  • 19 Oct 2016 Research programme : enzyme replacement therapy - Swedish Orphan Biovitrum (Sobi) receives Orphan Drug status for Mucopolysaccharidosis III in European Union
  • 19 Oct 2016 Swedish Orphan Biovitrum plans a clinical trial for mucopolysaccharidosis type IIIA (Sanfilippo A syndrome)
  • 01 Oct 2015 Preclinical trials in Inborn error metabolic disorders in Sweden (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top